Detecting inclusion body myositis
AssigneesChildren's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
InventorsSteven A. Greenberg, Mohammad K. Salajegheh
Life of this patent
Estimating the term…
Abstract
Methods, devices, kits and systems for diagnosing inclusion body myositis (IBM) are provided. Methods, devices, kits and systems involves detecting the presence and/or level of autoantibodies that are reactive against at least a ˜43 kilodalton (kDa) protein or ˜43 kDa protein band from a muscle lysate or a mammalian cell lysate, or autoantibodies that are reactive against a cytosolic 5′-nucleotidase 1A protein (NT5C1A), or a cytosolic 5′-nucleotidase 1B protein (NT5C1B), or a NT5C1B isoform thereof, or a peptide fragment thereof, an isolated peptide thereof or a fusion protein comprising an isolated peptide of NT5C1A or NT5C1B. Such autoantibodies are only found in IBM patients and not in patients with other myopathies.
Claims21
1-52. (canceled)
A method of identifying the presence of a circulating autoantibody against a ˜43-kDa muscle protein that is specific to inclusion body myositis (IBM), the method comprising
- a. performing an immunoblot assay with a plasma sample from a patient with an inflammatory myopathy against a normal human muscle lysate;
- and
- b. detecting the presence for a reactivity to an ˜43-kDa muscle protein on the immunoblot.
A method of identifying the presence of a circulating autoantibody against a 43-kDa muscle protein that is specific to inclusion body myositis (IBM), the method comprising
- a. providing a plasma sample from a patient with an inflammatory myopathy;
- b. probing the plasma sample against a normal human muscle lysate;
- and
- c. detecting the presence for a reactivity of the plasma sample to an ˜43-kDa muscle protein from the muscle lysate.
A method of aiding diagnosis of inclusion body myositis (IBM), the method comprising detecting the presence of a circulating autoantibody against a 43-kDa muscle protein that is specific to IBM, wherein the detecting comprising
- a. performing an immunoblot assay with a plasma sample from a patient suspected of having an inflammatory myopathy against a normal human muscle lysate;
- and
- b. detecting the presence for a reactivity to an ˜43-kDa muscle protein on the immunoblot.
A method of aiding diagnosis of inclusion body myositis (IBM), the method comprising detecting the presence of a circulating autoantibody against a 43-kDa muscle protein that is specific to IBM, wherein the detecting comprising:
- a. providing a plasma sample from a patient suspected of having an inflammatory myopathy;
- b. probing the plasma sample against a normal human muscle lysate;
- and
- c. detecting the presence for a reactivity of the plasma sample to an ˜43-kDa muscle protein from the muscle lysate.
Dependencies are inferred from the claim text.